Literature DB >> 35927303

Phosphorylation of OTUB1 at Tyr 26 stabilizes the mTORC1 component, Raptor.

Seung Un Seo1, Seon Min Woo1, Min Wook Kim2, Eun-Woo Lee3,4, Kyoung-Jin Min5, Taeg Kyu Kwon6,7.   

Abstract

Raptor plays a critical role in mTORC1 signaling. High expression of Raptor is associated with resistance of cancer cells to PI3K/mTOR inhibitors. Here, we found that OTUB1-stabilized Raptor in a non-canonical manner. Using biochemical assays, we found that the tyrosine 26 residue (Y26) of OTUB1 played a critical role in the interaction between OTUB1 and Raptor. Furthermore, non-receptor tyrosine kinases (Src and SRMS kinases) induced phosphorylation of OTUB1 at Y26, which stabilized Raptor. Interestingly, phosphorylation of OTUB1 at Y26 did not affect the stability of other OTUB1-targeted substrates. However, dephosphorylation of OTUB1 destabilized Raptor and sensitized cancer cells to anti-cancer drugs via mitochondrial reactive oxygen species-mediated mitochondrial dysfunction. Furthermore, we detected high levels of phospho-OTUB1 and Raptor in samples of patients with renal clear carcinoma. Our results suggested that regulation of OTUB1 phosphorylation may be an effective and selective therapeutic target for treating cancers via down-regulation of Raptor.
© 2022. The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare.

Entities:  

Year:  2022        PMID: 35927303     DOI: 10.1038/s41418-022-01047-3

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   12.067


  47 in total

Review 1.  Differentiating mTOR inhibitors in renal cell carcinoma.

Authors:  Sumanta K Pal; David I Quinn
Journal:  Cancer Treat Rev       Date:  2013-02-21       Impact factor: 12.111

2.  Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.

Authors:  Jianing Xu; Can G Pham; Steven K Albanese; Yiyu Dong; Toshinao Oyama; Chung-Han Lee; Vanessa Rodrik-Outmezguine; Zhan Yao; Song Han; David Chen; Daniel L Parton; John D Chodera; Neal Rosen; Emily H Cheng; James J Hsieh
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

3.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.

Authors:  David A Guertin; Deanna M Stevens; Carson C Thoreen; Aurora A Burds; Nada Y Kalaany; Jason Moffat; Michael Brown; Kevin J Fitzgerald; David M Sabatini
Journal:  Dev Cell       Date:  2006-12       Impact factor: 12.270

4.  The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.

Authors:  Daniel C Cho; Matthew B Cohen; David J Panka; Michael Collins; Musie Ghebremichael; Michael B Atkins; Sabina Signoretti; James W Mier
Journal:  Clin Cancer Res       Date:  2010-07-06       Impact factor: 12.531

5.  Activation of the mTOR signaling pathway in renal clear cell carcinoma.

Authors:  Victoria A Robb; Magdalena Karbowniczek; Andres J Klein-Szanto; Elizabeth P Henske
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

6.  mTOR inhibitors in renal cell carcinoma.

Authors:  Chiara Battelli; Daniel C Cho
Journal:  Therapy       Date:  2011-07

7.  Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.

Authors:  Allan J Pantuck; David B Seligson; Tobias Klatte; Hong Yu; John T Leppert; Laurence Moore; Timothy O'Toole; Jay Gibbons; Arie S Belldegrun; Robert A Figlin
Journal:  Cancer       Date:  2007-06-01       Impact factor: 6.860

Review 8.  The mTOR signalling pathway in human cancer.

Authors:  Helena Pópulo; José Manuel Lopes; Paula Soares
Journal:  Int J Mol Sci       Date:  2012-02-10       Impact factor: 6.208

Review 9.  mTORC1 and mTORC2 in cancer and the tumor microenvironment.

Authors:  L C Kim; R S Cook; J Chen
Journal:  Oncogene       Date:  2016-10-17       Impact factor: 9.867

Review 10.  Mechanisms of adverse effects of anti-VEGF therapy for cancer.

Authors:  T Kamba; D M McDonald
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.